BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward

blonca9
Nov 4, 2024
1 min read

CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x 5T4 bispecifics the company is developing.

Brought to you by

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight